Tradestie Institutional Equity Comparison Engine

CGON vs RGNX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CGON Overall Edge

CGON Captures Institutional Edge (3โ€“1 Pillars ยท 5โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CG Oncology, Inc. Common stock (CGON) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while RGNX counters with relative strength in Valuation. Fundamentally, CGON trades at N/M Forward P/E with -4293.5% operating margin (-3.7% YoY revenue) versus RGNX at N/M Forward P/E and -120.4% operating margin (-69.2% YoY). In options structure, CGON sits in CONSOLIDATION (85th %ile IV; Dealer Gamma Walls on Pro) against RGNX sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner RGNX
CGON N/M vs RGNX N/M Fwd P/E
Growth & Margin Winner CGON
Op Margin -4293.5% vs -120.4% ยท YoY -3.7% vs -69.2%
Momentum & Technical Winner CGON
1Y +124.9% vs -36.0% ยท 52W Pos 84% vs 19%
Options & Structure Winner CGON
CONSOLIDATION (85th %ile IV) vs BREAKDOWN (52nd %ile IV)
CGON NASDAQ
CG Oncology, Inc. Common stock
Biological Products, (No Disgnostic Substances)
$84.94
+14.16% 1D
Market Cap $6.3B
1M Return +41.91%
1Y Return +124.93%
Forward P/E N/M
Unified AI Score
45.0 / 100 HOLD
Tech 15.0 Fund 44.0 Flow 69.0 Mom 60.0
RGNX NASDAQ
REGENXBIO Inc.
Biological Products, (No Disgnostic Substances)
$7.45
-2.49% 1D
Market Cap $500.9M
1M Return +7.58%
1Y Return -36.0%
Forward P/E N/M
Unified AI Score
45.3 / 100 HOLD
Tech 36.0 Fund 44.0 Flow 69.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CGON +124.93% RGNX -36.0% Spread: +160.93 pp (CGON Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period CGON Revenue RGNX Revenue CGON Op. Margin RGNX Op. Margin Margin Edge
FY2018 N/A $220M N/A 40.3% RGNX
FY2019 N/A $40M N/A -422.9% RGNX
FY2020 N/A $150M N/A -77.1% RGNX
FY2021 N/A $470M N/A 34.0% RGNX
FY2022 N/A $110M N/A -233.2% RGNX
FY2023 $0M $90M -27180.9% -297.1% RGNX
FY2024 $0M $80M -10067.3% -280.0% RGNX
FY2025 $0M $170M -4722.1% -94.6% RGNX

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CGON (5) vs RGNX (3)
Institutional Metric CGON RGNX Criterion Row Winner
Market Capitalization Scale $6.3B $500.9M Larger Scale CGON
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -3.7% -69.2% Higher Growth CGON
Operating Margin (TTM) Profitability -4293.5% -120.4% Higher Margin RGNX
Net Profit Margin Profitability 0.0% -113.9% Higher Margin CGON
Return on Equity (ROE) Capital Efficiency -28.3% -113.2% Higher ROE CGON
52-Week Range Position Momentum 84% ($37โ€“$94) 19% ($5โ€“$16) Stronger Trend CGON
Beta / 30D Volatility Risk Regime 0.77ฮฒ ยท 86% Vol 1.82ฮฒ ยท 76% Vol Lower Realized Risk RGNX
Unified Institutional Score Composite Signal 45.0 / 100 (HOLD) 45.3 / 100 (HOLD) Higher Composite RGNX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CGON vs RGNX Buy Guide
CGON CONSOLIDATION
62d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 85th %ile
IV Regime Extreme (>80th %ile)
Live CGON Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
RGNX BREAKDOWN
91d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live RGNX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CGON nor RGNX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.